ZA201002445B - Hiv preventive vaccine based on hiv specific antibodies - Google Patents

Hiv preventive vaccine based on hiv specific antibodies

Info

Publication number
ZA201002445B
ZA201002445B ZA2010/02445A ZA201002445A ZA201002445B ZA 201002445 B ZA201002445 B ZA 201002445B ZA 2010/02445 A ZA2010/02445 A ZA 2010/02445A ZA 201002445 A ZA201002445 A ZA 201002445A ZA 201002445 B ZA201002445 B ZA 201002445B
Authority
ZA
South Africa
Prior art keywords
hiv
specific antibodies
vaccine based
preventive vaccine
hiv specific
Prior art date
Application number
ZA2010/02445A
Other languages
English (en)
Inventor
Elena Yu Filinova
Original Assignee
Tech Integrate Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tech Integrate Ltd filed Critical Tech Integrate Ltd
Publication of ZA201002445B publication Critical patent/ZA201002445B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/02445A 2007-10-09 2010-04-07 Hiv preventive vaccine based on hiv specific antibodies ZA201002445B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853607P 2007-10-09 2007-10-09
PCT/EP2008/008544 WO2009046984A1 (en) 2007-10-09 2008-10-09 Hiv preventive vaccine based on hiv specific antibodies

Publications (1)

Publication Number Publication Date
ZA201002445B true ZA201002445B (en) 2011-03-30

Family

ID=40342551

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/02445A ZA201002445B (en) 2007-10-09 2010-04-07 Hiv preventive vaccine based on hiv specific antibodies

Country Status (12)

Country Link
US (1) US20100215695A1 (enExample)
EP (1) EP2205736B1 (enExample)
JP (1) JP2010540674A (enExample)
KR (1) KR20100098597A (enExample)
CN (1) CN101970659A (enExample)
AU (1) AU2008309940B2 (enExample)
BR (1) BRPI0818354A2 (enExample)
CA (1) CA2701948A1 (enExample)
MX (1) MX2010003762A (enExample)
RU (1) RU2505604C2 (enExample)
WO (1) WO2009046984A1 (enExample)
ZA (1) ZA201002445B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422618A1 (en) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102190726B (zh) * 2011-03-30 2013-03-27 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
HK1200359A1 (zh) * 2011-09-17 2015-08-07 源道隆（苏州）医学科技有限公司 任意三个或以上氨基酸残基构成的多肽表位及其相关抗体的诱导
US10660951B2 (en) 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
RU2600031C2 (ru) * 2014-11-11 2016-10-20 Публичное акционерное общество "Фармсинтез" Лекарственная форма специфического иммунобиологического лекарственного средства для лечения и профилактики вич инфекции и способ ее получения
ES2959642T3 (es) * 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
EP3464348A4 (en) * 2016-05-25 2020-01-22 University Of Maryland, Baltimore METHOD FOR PRODUCING ACTIVE ANTIBODIES FROM BIOLOGICAL LIQUIDS
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
WO2018237357A1 (en) 2017-06-22 2018-12-27 University Of Maryland, Baltimore HIV-LARGE SPECTRUM HIV NEUTRALIZATION ANTIBODIES AGAINST HIV
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
IT202100004160A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Cellula ospite di leishmania
IT202100004172A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Nuova composizione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV

Also Published As

Publication number Publication date
BRPI0818354A2 (pt) 2017-05-16
KR20100098597A (ko) 2010-09-08
AU2008309940B2 (en) 2013-11-14
RU2505604C2 (ru) 2014-01-27
MX2010003762A (es) 2010-09-10
EP2205736A1 (en) 2010-07-14
EP2205736B1 (en) 2014-04-02
JP2010540674A (ja) 2010-12-24
AU2008309940A1 (en) 2009-04-16
WO2009046984A1 (en) 2009-04-16
CA2701948A1 (en) 2009-04-16
US20100215695A1 (en) 2010-08-26
CN101970659A (zh) 2011-02-09
RU2010116849A (ru) 2011-11-20

Similar Documents

Publication Publication Date Title
ZA200904923B (en) Vaccine
GB0607088D0 (en) Vaccine
IL201782A0 (en) Vaccine
GB0717911D0 (en) Vaccine
GB0711858D0 (en) Vaccine
IL206307A0 (en) Vaccine
BRPI0818354A2 (pt) vacina preventiva do hiv baseada em anticorpos específicos para o hiv
GB0710538D0 (en) Vaccine
GB0700135D0 (en) Vaccine
ZA201003851B (en) Vaccine
ZA200901592B (en) Vaccine
GB0709373D0 (en) BCG-based anti-atheroma vaccine
GB0625593D0 (en) Vaccine
GB0711357D0 (en) Vaccine
GB0712428D0 (en) Vaccine
GB0700760D0 (en) Vaccine
GB0721928D0 (en) Vaccine
GB0712062D0 (en) Vaccine
GB0708522D0 (en) Vaccine
GB0725107D0 (en) Vaccine
GB0706540D0 (en) Anti-atheroma vaccine
GB0725121D0 (en) Vaccine
GB0712435D0 (en) Vaccine
GB0707697D0 (en) Vaccine
GB0713188D0 (en) Vaccine